Newsletter Tool

Featured Story

Leaping forward: Bayer VC arm commits $1.4B to double investment pace through 2024

By Max Bayer

Leaps by Bayer, the investment arm of the Big Pharma, plans to more than double the pace of its investments through 2024 with another €1.3 billion for new ventures through 2024.

Senate close to bipartisan $10B deal on COVID-19 relief, but provider dollars may be absent

By Robert King

Senators say they are close to a bipartisan deal on $10 billion in COVID-19 relief funding but won't include dedicated money to reimburse providers for uninsured claims.

After decades, researchers deliver first complete human genome using long-read DNA sequencers

By Conor Hale

Spanning 23 chromosomes and more than 3 billion individual nucleotides in total, the new data maps out the last untapped 8% of the genome, home to difficult-to-parse regions made up of long stretches of repetitive DNA.

Merck, amid pneumococcal vaccine race with Pfizer, suffers FDA delay for key pediatric use

By Kevin Dunleavy

The FDA has extended its target date for approval of Merck's next-generation pneumococcal vaccine Vaxneuvance in kids by three months. Before it signs off the shot for kids ages 6 weeks through 17, the U.S. regulator wants to see additional analyses of data. The approval is key as Merck hopes to gain an edge over Pfizer in this important age group.

Medtronic recalls 6,000 drug-coated balloons shipped in potentially unsterile packaging

By Andrea Park

Patients who have already undergone procedures using the recalled products don’t need to take any additional precautions, Medtronic said, but should continue to be monitored in line with their healthcare provider’s standard post-op practices.

Sage's phase 2 Alzheimer's drug shows signs of cognitive improvement—but there's a catch

By Annalee Armstrong

Sage Therapeutics was mostly focussed on reviewing safety for its Alzheimer’s disease drug, but early data shows the therapy may also improve executive performance, learning and memory in patients with mild cognitive impairment and dementia—but there's a catch.

AHA redirects FTC, DOJ merger scrutiny from hospital deals to concentrated insurer markets

By Dave Muoio

In a recent letter to DOJ and the FTC, the hospital trade group suggested limited, pro-merger changes to hospital antitrust guidelines and called on regulators to rein in insurers taking advantage of highly concentrated markets.

Bristol Myers CEO Caforio takes pay cut as 'human capital' metric drags down bonus

By Angus Liu

Bristol Myers Squibb is hoping new launches will offset a wave of forthcoming patent losses for some of its biggest-selling drugs. But in the meantime, CEO Giovanni Caforio just received a smaller pay package.

BD's Embecta diabetes spinoff leaves the nest as standalone billion-dollar company

By Andrea Park

No, it’s not an April Fool’s joke—BD officially bid farewell to its longstanding diabetes business on Friday, as the newly formed Embecta made its public debut on the Nasdaq.

SAB vows to plow ahead with COVID-19 therapy after NIH drops out

By Annalee Armstrong

SAB Biotherapeutics is hoping to continue work on its COVID-19 antibody treatment after the National Institutes of Health shut down a funded phase 3 clinical trial when the omicron wave slowed earlier this year.

Viatris, after closing massive West Virginia plant, sells it for $1